The approval was granted due to consistent results from the DAPA-CKD study, where the indication has now been recommended in adults with CKD up to an eGFR greater than or equal to 25 ml per min ...

This approval is applicable for both diabetic and non-diabetic CKD patients. “The approval is based on the consistent results from the DAPA-CKD study, where the indication has now been ...

They point out, too, that the hazard ratios all signal a benefit with empagliflozin, consistent with trials of other SGLT2 inhibitors, such as DAPA-CKD and CREDENCE. Indeed, Preiss reported, when the ...

That drug was shown in a 2020 trial, known as DAPA-CKD, to cut by 39% the risk of kidney disease progression, or death from kidney or cardiovascular causes. Compared with AstraZeneca's trial ...

and DAPA-CKD in CKD, which established Forxiga as the first SGLT2 inhibitor approved for use in these indications. We drive value outside of the main or first indication to discover where a mode of ...

The study, titled “Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients with CKD” (Dapa-CKD), was participated in by 4,304 CKD patients from 21 countries, 115 of whom were ...

The company represented standard care using the placebo arm of DAPA‑CKD (see section 3.7). This comprised of background therapies including ACE inhibitors or ARBs, statins and antiplatelets. The ERG ...

The condition is a considerable burden on the UK healthcare system, representing 1.3% of NHS spending in total. The DAPA-CKD phase 3 trial formed the basis of NICE’s recommendation, which demonstrated ...

The medications increase urinary sodium and glucose excretion. The CREDENCE and DAPA-CKD trials found decreased risk for CKD progression and cardiovascular benefits from these drugs. There is not ...

The same could apply to diseases clustered around chronic kidney disease (CKD). However, these clusters and patterns will still result in some patients (eg, needing oncological or ophthalmological ...